Status:

COMPLETED

Hypertension in Patients Hospitalized With COVID-19

Lead Sponsor:

Zhenhua Zen

Conditions:

COVID-19

Hypertension

Eligibility:

All Genders

18-100 years

Brief Summary

Some studies have shown that the main pathogenesis of patients with covid19 is related to ACE2 receptor. Lung is one of the main organs, and there are many ACE2 receptors in cardiovascular system. ACE...

Detailed Description

In December, 2019, a cluster of severe pneumonia cases of unknown cause emerged in Wuhan, China, with clinical presentations greatly resembling viral pneumonia1. Deep sequencing analysis from lower re...

Eligibility Criteria

Inclusion

  • COVID-19 pneumonia patients diagnosed by WHO criteria

Exclusion

  • Patients who were younger than 18 years.
  • Patients whose entire stay lasted for less than 48 hours.

Key Trial Info

Start Date :

March 21 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 30 2020

Estimated Enrollment :

275 Patients enrolled

Trial Details

Trial ID

NCT04318301

Start Date

March 21 2020

End Date

March 30 2020

Last Update

April 29 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hankou Hospital

Hankou, Hubei, China, 430000